Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment
Authors' conclusion
In paediatric patients with FH, 80 weeks of open-label evolocumab treatment had no negative impact on cognitive function.
Study context
- Population
- Paediatric patients (ages 10–17 years) with heterozygous familial hypercholesterolaemia (FH); all received monthly 420 mg subcutaneous evolocumab during the OLE
- Comparison
- Evolocumab over 80 weeks; prior placebo vs prior evolocumab in the RCT
- Primary endpoint
- Cognitive function (psychomotor function, attention, visual learning, executive function)
- Follow-up
- 80 weeks of OLE
Methodological detailssingle-arm extension
- Single-arm extension
Primary result
As reported in the abstract
Cognitive function · 80 weeks
- No decrease in performance across visits for Groton Maze Learning, One Card Learning accuracy, Identification speed or Detection speed
- all P > 0.05
- Performance on all tasks similar for prior placebo vs evolocumab
- all P > 0.05
- LS mean differences between prior placebo vs evolocumab trivial
- all Cohen's d magnitude < 0.2
Original publication
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. Published 19 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →